The clinical potential of novel erythropoiesis stimulating protein.
Novel erythropoiesis stimulating protein (NESP) is a supersialylated analogue of endogenous erythropoietin or recombinant human erythropoietin (rhuEPO). It contains a total of five N-linked consensus carbohydrate binding sites in the native protein. NESP has a higher molecular weight due to an increased content of carbohydrates, which, however, has no meaningful influence on the binding to and activation of the erythropoietin receptor. The major difference in comparison to rhuEPO is the up to threefold increase of the terminal half-life of NESP, which allows for less frequent dosing of NESP. Several clinical studies have shown that NESP is as safe and efficient as rhuEPO in correcting renal anaemia and in the maintenance therapy of renal anaemia.
Sunder-Plassmann
G
G
Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Austria. Gere.Sunder-Plassmann@akh-wien.ac.at
Hörl
W H
WH
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000188:drug therapy*; D000818:Animals; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D017467:Receptors, Erythropoietin / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects
D006454:Hemoglobins; D017467:Receptors, Erythropoietin; D004921:Erythropoietin; D000068256:Darbepoetin alfa